ValuEngine Upgrades Innovus Pharmaceuticals (INNV) to “Sell”
ValuEngine upgraded shares of Innovus Pharmaceuticals (OTCMKTS:INNV) from a strong sell rating to a sell rating in a research report report published on Friday.
Separately, Zacks Investment Research raised Innovus Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 24th.
Innovus Pharmaceuticals (INNV) opened at $0.15 on Friday. Innovus Pharmaceuticals has a 12-month low of $0.08 and a 12-month high of $0.39. The firm has a market capitalization of $24.25, a PE ratio of -2.11 and a beta of 4.41.
About Innovus Pharmaceuticals
Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.